



Date: 09.01.2024

To,
Listing Operations Department,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

Scrip ID/Code: GENPHARMA/ 531592

ISIN: INE861N01036

Subject: Outcome of the Right Issue Committee - Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "SEBI Listing Regulations") – Approval of Letter of Offer.

Dear Sir,

This is in furtherance to our intimation on the outcome of the meeting of the Right Issue Committee of the Board of Directors of the Company ("Board") held on 03rd January, 2024 and intimation of record date, this is to inform you that the Right Issue Committee in its meeting held today, i.e., 09th January, 2024, has approved the Letter of Offer, Abridged Letter of Offer, etc. for the Rights Issue of the Company which is scheduled to be opened on January 22, 2024 and to be closed on February 09, 2024.

The terms related to offer price and rights entitlement ratio will remain the same as approved by the Right Issue Committee and intimated to the stock exchange earlier.

We request you to take the above on record and that the same be treated as compliance under the applicable regulation(s) under the SEBI Listing Regulations.

The meeting is concluded at 04:40 P.M.

Thanks & Regards,

For Genpharmasec Limited

ULHAS
NARAYAN
DEOSTHALE
Digitally signed by
ULHAS NARAYAN
DEOSTHALE
Date: 2024.01.09
16:40:55 +05'30'

Ulhas Deosthale
Whole Time Director
DIN : 09215291

